Equity Analysis /

MY : Duopharma Biotech Bhd - 2Q22 a beat; upgrade on valuation grounds

    17 August 2022
    Published byCGS-CIMB

    1H22 core EPS was a beat on low cost and depreciation; up 52% yoy. Local sales grew strongly again, while EBITDA margin managed to hold up. Upgrade to Add with higher TP of RM1.70, given more appealing valuations.